Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)
87,100
+2,800 (3.32%)
Apr 10, 2026, 3:30 PM KST
Mezzion Pharma Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 25,574 | 13,617 | 40,246 | 29,399 | 24,210 |
Short-Term Investments | - | 15,000 | 18,000 | 3,000 | 23,284 |
Cash & Short-Term Investments | 25,574 | 28,617 | 58,246 | 32,399 | 47,494 |
Cash Growth | -10.63% | -50.87% | 79.78% | -31.78% | -3.28% |
Accounts Receivable | 1,078 | 869.93 | 2,309 | 2,644 | 2,368 |
Other Receivables | 202.26 | 457.47 | 2,154 | 238.76 | 377.57 |
Receivables | 1,990 | 1,757 | 5,925 | 4,203 | 4,435 |
Inventory | 5,302 | 5,420 | 5,742 | 8,835 | 11,777 |
Prepaid Expenses | 113.77 | 127.5 | 136.44 | 265.05 | 266.77 |
Other Current Assets | 12,606 | 6,004 | 4,194 | 195.28 | 201.3 |
Total Current Assets | 45,586 | 41,926 | 74,244 | 45,897 | 64,174 |
Property, Plant & Equipment | 2,516 | 2,529 | 2,854 | 4,245 | 4,879 |
Long-Term Investments | 0 | 3.08 | 7.46 | - | -0 |
Other Intangible Assets | 1,620 | 1,620 | 1,620 | 1,620 | 1,620 |
Long-Term Deferred Charges | 47,498 | 26,820 | 11,324 | - | 12,559 |
Other Long-Term Assets | 694.49 | 821.1 | 1,951 | 1,950 | 672.93 |
Total Assets | 98,025 | 73,998 | 92,149 | 54,022 | 83,935 |
Accounts Payable | 1,810 | 1,646 | 4,030 | 7,173 | 5,503 |
Accrued Expenses | 23,692 | 18,882 | 21,831 | - | 7,188 |
Short-Term Debt | 9,910 | - | 499.58 | 1,063 | 932.01 |
Current Portion of Leases | 812.5 | 694.38 | 735.87 | - | 1,051 |
Current Income Taxes Payable | - | 3,892 | - | - | - |
Other Current Liabilities | 43,349 | 1,556 | 2,519 | 17,844 | 3,823 |
Total Current Liabilities | 79,572 | 26,670 | 29,615 | 26,080 | 18,497 |
Long-Term Leases | 1,151 | 921.47 | 1,005 | - | 2,338 |
Pension & Post-Retirement Benefits | - | - | - | - | 217.2 |
Long-Term Deferred Tax Liabilities | - | 251.42 | - | - | - |
Other Long-Term Liabilities | 106.62 | 91.98 | 84.61 | 1,702 | 89.78 |
Total Liabilities | 80,830 | 27,935 | 30,705 | 27,782 | 21,141 |
Common Stock | 15,182 | 14,982 | 14,804 | 13,371 | 4,451 |
Additional Paid-In Capital | 173,602 | 159,062 | 150,510 | 99,256 | 107,802 |
Retained Earnings | -178,129 | -143,148 | -123,723 | -111,052 | -74,789 |
Comprehensive Income & Other | 6,539 | 15,167 | 19,854 | 24,665 | 25,330 |
Shareholders' Equity | 17,195 | 46,063 | 61,444 | 26,240 | 62,793 |
Total Liabilities & Equity | 98,025 | 73,998 | 92,149 | 54,022 | 83,935 |
Total Debt | 11,873 | 1,616 | 2,241 | 1,063 | 4,321 |
Net Cash (Debt) | 13,701 | 27,001 | 56,006 | 31,336 | 43,173 |
Net Cash Growth | -49.26% | -51.79% | 78.73% | -27.42% | -1.88% |
Net Cash Per Share | 455.01 | 905.27 | 1983.28 | 1172.20 | 1617.75 |
Filing Date Shares Outstanding | 30.32 | 29.96 | 29.61 | 26.74 | 26.7 |
Total Common Shares Outstanding | 30.32 | 29.96 | 29.61 | 26.74 | 26.7 |
Working Capital | -33,987 | 15,255 | 44,628 | 19,817 | 45,678 |
Book Value Per Share | 567.14 | 1537.30 | 2075.31 | 981.23 | 2351.55 |
Tangible Book Value | 15,575 | 44,443 | 59,825 | 24,620 | 61,174 |
Tangible Book Value Per Share | 513.72 | 1483.24 | 2020.60 | 920.66 | 2290.89 |
Buildings | - | - | - | 23.97 | 23.97 |
Machinery | 2,183 | 2,191 | 1,976 | 3,523 | 2,908 |
Construction In Progress | - | - | 619.69 | 439.17 | 193.43 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.